Wells Fargo Raises Bristol-Myers Squibb Price Target to $60.00

Wells Fargo has raised its price target for Bristol-Myers Squibb (BMY) from $55 to $60, a 9.09% increase, while maintaining its "Equal-Weight" rating. Analyst Mohit Bansal made the adjustment, following recent analyst activities including upgrades and price target increases from Piper Sandler, Citigroup, Leerink Partners, Scotiabank, and UBS. The average target price for BMY is $57.56 with a high estimate of $68 and a low estimate of $33.10, indicating a 6.94% downside from the current price of $61.85.